

Highlights of This Issue 509

SPECIAL FEATURES

CCR Translations

- 511 | **Breast Cancer Stem Cells: We've Got Them Surrounded**
Hasan Korkaya and Max S. Wicha
See article, p. 643
- 514 | **A Focus on PD-L1 in Human Melanoma**
Peter Hersey and Stuart Gallagher
See article, p. 598

CCR New Strategies

- 517 | **New Strategies in Prostate Cancer: Translating Genomics into the Clinic**
Himisha Beltran and Mark A. Rubin

CCR Drug Updates

- 524 | **Vandetanib for the Treatment of Medullary Thyroid Cancer**
Nicole G. Chau and Robert I. Haddad

Molecular Pathways

- 530 | **Molecular Pathways: Targeted α -Particle Radiation Therapy**
Kwamena E. Baidoo, Kwon Yong, and Martin W. Brechbiel

Perspective

- 538 | **Changing the Way We Do Business: Recommendations to Accelerate Biomarker Development in Pancreatic Cancer**
Margaret A. Tempero, David Klimstra, Jordan Berlin, Tony Hollingsworth, Paula Kim, Nipun Merchant, Malcolm Moore, Doug Pleskow, Andrea Wang-Gillam, and Andrew M. Lowy

Review

- 541 | **Does Microenvironment Contribute to the Etiology of Estrogen Receptor-Negative Breast Cancer?**
Mary Helen Barcellos-Hoff

HUMAN CANCER BIOLOGY

- 549 | **Deciphering the Mechanisms of Tumorigenesis in Human Pancreatic Ductal Epithelial Cells**
Zhe Chang, Zhongkui Li, Xiaoyang Wang, Ya'an Kang, Yuhui Yuan, Jiangong Niu, Huamin Wang, Deyali Chatterjee, Jason B. Fleming, Min Li, James L. Abbruzzese, and Paul J. Chiao
- 560 | **SLC1A5 Mediates Glutamine Transport Required for Lung Cancer Cell Growth and Survival**
Mohamed Hassanein, Megan D. Hoeksema, Masakazu Shiota, Jun Qian, Bradford K. Harris, Heidi Chen, Jonathan E. Clark, William E. Alborn, Rosana Eisenberg, and Pierre P. Massion
- 571 | **Impact of Tumor Microenvironment and Epithelial Phenotypes on Metabolism in Breast Cancer**
Heather Ann Brauer, Liza Makowski, Katherine A. Hoadley, Patricia Casbas-Hernandez, Lindsay J. Lang, Erick Román-Pérez, Monica D'Arcy, Alex J. Freermerman, Charles M. Perou, and Melissa A. Troester

CANCER THERAPY: PRECLINICAL

- 586 | **Sorafenib Inhibits Cell Migration and Stroma-Mediated Bortezomib Resistance by Interfering B-cell Receptor Signaling and Protein Translation in Mantle Cell Lymphoma**
Silvia Xargay-Torrent, Mónica López-Guerra, Arnau Montraveta, Ifigènia Saborit-Villarroya, Laia Rosich, Alba Navarro, Patricia Pérez-Galán, Gaël Roué, Elias Campo, and Dolors Colomer
- 598 | **The Activation of MAPK in Melanoma Cells Resistant to BRAF Inhibition Promotes PD-L1 Expression That Is Reversible by MEK and PI3K Inhibition**
Xiaofeng Jiang, Jun Zhou, Anita Giobbie-Hurder, Jennifer Wargo, and F. Stephen Hodi
See commentary, p. 514
- 610 | **Dual Blockade of HER2 in HER2-Overexpressing Tumor Cells Does Not Completely Eliminate HER3 Function**
Joan T. Garrett, Cammie R. Sutton, María Gabriela Kuba, Rebecca S. Cook, and Carlos L. Arteaga

- 620 **A Potent Combination of the Novel PI3K Inhibitor, GDC-0941, with Imatinib in Gastrointestinal Stromal Tumor Xenografts: Long-Lasting Responses after Treatment Withdrawal**
Giuseppe Floris, Agnieszka Wozniak, Raf Sciot, Haifu Li, Lori Friedman, Thomas Van Looy, Jasmien Wellens, Peter Vermaelen, Christophe M. Deroose, Jonathan A. Fletcher, Maria Debiec-Rychter, and Patrick Schöffski
- 631 **Impairment of Glioma Stem Cell Survival and Growth by a Novel Inhibitor for Survivin-Ran Protein Complex**
Hacer Guvenc, Marat S. Pavlyukov, Kaushal Joshi, Habibe Kurt, Yeshavanth K. Banasavadi-Siddegowda, Ping Mao, Christopher Hong, Ryosuke Yamada, Chang-Hyuk Kwon, Deepak Bhasin, Somsundaram Chettiar, Gaspar Kitange, In-Hee Park, Jann N. Sarkaria, Chenglong Li, Mihail I. Shakhparonov, and Ichiro Nakano
- 643 **Targeting CXCR1/2 Significantly Reduces Breast Cancer Stem Cell Activity and Increases the Efficacy of Inhibiting HER2 via HER2-Dependent and -Independent Mechanisms**
Jagdeep K. Singh, Gillian Farnie, Nigel J. Bundred, Bruno M Simões, Amrita Shergill, Göran Landberg, Sacha J. Howell, and Robert B. Clarke
See commentary, p. 511
- 657 **Resistance to BRAF Inhibition in BRAF-Mutant Colon Cancer Can Be Overcome with PI3K Inhibition or Demethylating Agents**
Muling Mao, Feng Tian, John M. Mariadason, Chun C. Tsao, Robert Lemos Jr, Farshid Dayyani, Y.N. Vashisht Gopal, Zhi-Qin Jiang, Ignacio I. Wistuba, Xi M. Tang, William G. Bornman, Gideon Bollag, Gordon B. Mills, Garth Powis, Jayesh Desai, Gary E. Gallick, Michael A. Davies, and Scott Kopetz
- 668 **Systemic Administration of a Novel Immune-Stimulatory Pseudovirion Suppresses Lung Metastatic Melanoma by Regionally Enhancing IFN- γ Production**
Kotaro Saga, Katsuto Tamai, Takehiko Yamazaki, and Yasufumi Kaneda
- 680 **Antitumor Activity of Cell-Permeable RUNX3 Protein in Gastric Cancer Cells**
Junghee Lim, Tam Duong, Nga Do, Phuong Do, Jaetaek Kim, Hyuncheol Kim, Wael El-Rifai, H. Earl Ruley, and Daewoong Jo

IMAGING, DIAGNOSIS, PROGNOSIS

- 691 **Effective Assessment of *egfr* Mutation Status in Bronchoalveolar Lavage and Pleural Fluids by Next-Generation Sequencing**
Fiamma Buttitta, Lara Felicioni, Maela Del Grammastro, Giampaolo Filice, Alessia Di Lorito, Sara Malatesta, Patrizia Viola, Irene Centi, Tommaso D'Antuono, Roberta Zappacosta, Sandra Rosini, Franco Cuccurullo, and Antonio Marchetti
- 699 **Molecular Markers in Key Steroidogenic Pathways, Circulating Steroid Levels, and Prostate Cancer Progression**
Éric Lévesque, Shu-Pin Huang, Étienne Audet-Walsh, Louis Lacombe, Bo-Ying Bao, Yves Fradet, Isabelle Laverdière, Mélanie Rouleau, Chao-Yuan Huang, Chia-Cheng Yu, Patrick Caron, and Chantal Guillemette
- 710 **Detection of *miR-34a* Promoter Methylation in Combination with Elevated Expression of c-Met and β -Catenin Predicts Distant Metastasis of Colon Cancer**
Helge Siemens, Jens Neumann, Rene Jackstadt, Ulrich Mansmann, David Horst, Thomas Kirchner, and Heiko Hermeking

CANCER THERAPY: CLINICAL

- 721 **γ -H2AX Foci Formation as a Pharmacodynamic Marker of DNA Damage Produced by DNA Cross-Linking Agents: Results from 2 Phase I Clinical Trials of SJG-136 (SG2000)**
Jenny Wu, Peter H. Clingen, Victoria J. Spanswick, Maria Mellinas-Gomez, Tim Meyer, Igor Puzanov, Duncan Jodrell, Daniel Hochhauser, and John A. Hartley

PREDICTIVE BIOMARKERS AND PERSONALIZED MEDICINE

- 731 **Serum CD163 and TARC as Disease Response Biomarkers in Classical Hodgkin Lymphoma**
Kimberley Jones, Frank Vari, Colm Keane, Pauline Crooks, Jamie P. Nourse, Louise A. Seymour, David Gottlieb, David Ritchie, Devinder Gill, and Maher K. Gandhi

743

A Phase II Study of Sorafenib in Patients with Platinum-Pretreated, Advanced (Stage IIIb or IV) Non-Small Cell Lung Cancer with a *KRAS* Mutation

Anne-Marie C. Dingemans,
Wouter W. Mellema, Harry J.M. Groen,
Atie van Wijk, Sjaak A. Burgers,
Peter W.A. Kunst, Erik Thunnissen,
Danielle A.M. Heideman, and Egbert F. Smit


CORRECTION

752

Correction: Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene *NR3C1*

ABOUT THE COVER

Cytology specimens may represent the only available material for molecular diagnosis in non-small cell lung cancer patients. When the number of neoplastic cells in these samples is very low in a large excess of nonneoplastic cells, the specimen is usually judged inadequate for mutation analysis with conventional methods. The cover figure shows a cytological smear obtained from a bronchoalveolar lavage with a limited number of tumor cells. Next-generation sequencing can greatly improve the detection of mutations in these cases. For details, see the article by Buttitta and colleagues on page 691 of this issue.



Clinical Cancer Research

19 (3)

Clin Cancer Res 2013;19:509-752.

Updated version Access the most recent version of this article at:
<http://clincancerres.aacrjournals.org/content/19/3>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://clincancerres.aacrjournals.org/content/19/3>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.